Loading...

KNSA KINIKSA PHARMACEUTICALS INTERNATIONAL PLC Earnings Reports 8-K Filing

KNKS

KNS

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC

(KNSA)

2026 8-K

Management Changes

Financial Results

Financial Results Announced

Investor Presentation Update

Financial Statements

Product Expansion

Management Changes

Product Expansion

License Termination

Financial Results

Q3 Earnings Report

Board Appointment

Earnings Reports

Agreement with Samsung Biol...

Redomiciliation

Annual Meeting and Special ...

Earnings Reports

Redomiciliation Proposal

Earnings Reports

Financial Results

Earnings Reports

Earnings Releases

Annual Meeting of Shareholders

Earnings Reports

Regulation FD Disclosure

Earnings Reports

Financial Results Announcement

External Links:

On January 12, 2026, Kiniksa Pharmaceuticals reported that its ARCALYST net product revenue reached $677.5 million for 2025, with a gross-to-net of 8.4%, and $414.1 million in cash and no debt as of year-end 2025.

AI Assistant

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.